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the National Health Care system perspective. Results: Preoperative characteris-
tics and risk scores of the 2 groups were comparable. Hospital mortality was 3.7% 
in Sutured and 2.4% in Sutureless (p= 0.65). Aortic cross-clamp, cardiopulmonary 
bypass time and operation time were 20%, 23% and 16% shorter in Sutureless (each 
one p< 0.001).Sutureless required less blood transfusion (1.2±1.3 vs 2.5±3.7 units, 
p= 0.005) with a similar incidence of postoperative bleeding (2 patients vs 5, p= 0.221). 
Sutureless had a shorter intensive care unit stay (2.0±1.72vs 2.8±1.3 days, p< 0.001), 
a shorter hospital stay (11.4±3.9 vs 17.3±13.7 days, p< 0.001) and a shorter intuba-
tion time (9.5±4.6 vs 16.6±6.4 hours, p< 0.001). A neurological event was recorded in 
3 sutureless patients and in 6 sutures (p= 0.248). Sutured has an higher incidence 
of postoperative atrial fibrillation, pleura effusions and respiratory insufficiency (p 
0.015, 0.024 and 0.016, respectively). Reduced risk of post operative complication 
resulted in a dramatic reduction of resources consumption in the sutureless group 
allowing a saving of 50% of the complication related resource use. ConClusions: 
Shorter procedural times resulting from sutureless aortic valve replacement are 
associated with better outcomes and lower costs. Sutureless valve may be consid-
ered as the first-line treatment for patients underwent aortic valve replacement 
with a bioprosthesis.
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objeCtives: To assess the annual average costs and quality adjusted life years 
(QALYs) of stroke services in the UK before and after the introduction of the National 
Stroke Strategy (period: 2006-2011). Methods: Data from the South London Stroke 
Register (SLSR) from 2006 to 2011 were used to populate a discrete event simulation 
(DES) model. Parameters, such as daily probability of survival and length of stay, 
included in the model were calculated by using Cox proportional hazard model and 
multivariate regression methods respectively. Barthel Index was used as proxy for 
measures of quality of life. Treatment costs were introduced in the model in order 
to calculate the total costs based on resource usage. The model simulated the stroke 
care delivery from stroke onset with 10-year follow up. Average cost and QALYs 
were calculated for every year from 2006 to 2011. Results: The average total costs 
per treating a stroke patient decreased from £30,745 to £27,086 between 2006 and 
2011 (p-value for trend < 0.001). This is mainly as a result of savings achieved in the 
inpatient phase due to a shorter LOS and a higher proportion of patients with mild 
disability. Per patient QALY’s also increased from 2.2 to 3.1 during the same period 
(p-value for trend < 0.001), this is due to a higher proportion of patients having 
access to better organised stroke care. ConClusions: This study has demonstrated 
that stroke services in the UK have improved their value for money over time with 
constant gains in efficiency. The use of DES together with SLSR data allows the test-
ing of the costs and outcomes of a whole stroke provision system or components 
of it and provide opportunities for retrospective (as done in this study) as well as 
prospective analysis (in the case of health technology assessment studies).
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objeCtives: To assess the impact of a hypothetical increase in the stroke primary 
preventive care coverage in the UK. Productivity gains, using resource utilization 
as proxy, and monetary benefits were calculated. Methods: Data from the South 
London Stroke Register (SLSR) from 2009 to 2011 were used to create a hypothetical 
cohort to populate a discrete event simulation (DES) model. The model simulated 
the stroke care delivery from primary preventive stroke care until discharge from 
stroke unit or general medical ward. Primary preventive care was defined as taking 
medications to control hypertension, high-cholesterol and also anticoagulants in 
patients with atrial fibrillation in order to prevent strokes. Treatment costs were 
introduced in the model in order to calculate the total costs based on resource usage. 
Hypothetical scenarios consisting in 10% incremental increase of primary preven-
tive care for high-risk factors were tested. The reduction of strokes was given by 
relative risk reduction ratios extracted from clinical trials. Results: Our findings 
indicate that for every 10% increase in the number of patients undergoing primary 
prevention treatment the number of strokes would be reduced by 1.2%. In a scenario 
where 50% of the untreated patients receive primary prevention 7,232 strokes would 
be reduced per year. For the same scenario, 47 hyper acute beds, 359 acute beds and 
47 general medical ward beds could be saved in average. In total this would yield in 
£42.2 million of savings in the inpatient phase of stroke care. ConClusions: Our 
findings suggest that by enhancing primary prevention of stroke care in the UK, 
significant benefits can be achieved in terms of reductions in resource consumption 
and monetary savings as a result of averted strokes. The generation and analysis 
of these retrospective hypothetical scenarios, using real-world evidence on stroke, 
help evaluate policy choices in stroke care in the UK.
PCV53
The Burden of resisTanT hyPerTension in 5 euroPean CounTries
Sapoval M.1, Hale B.C.2, Armstrong S.3, Da Deppo L.4, Hertz D.3, Briggs A.5
1Interventional Radiology Department, Assistance Publique des Hôpitaux de Paris, Georges 
Pompidou European Hospital, Paris, France, 2Boston Scientific, Natick, MA, USA, 3GfK Bridgehead, 
Wayland, MA, USA, 4Boston Scientific, Milan, Italy, 5University of Glasgow, Glasgow, UK
objeCtives: Greater than 40% of Europeans over age 25 have hypertension, and 10% 
of those have medication resistant hypertension (RHT). In EU5 (France, Germany, 
Italy, Spain, UK) that results in 9.4 million persons with blood pressure above goal, 
despite treatment with 3+ medications. These patients have a greater than 30% 
risk of cardiovascular disease (CVD) over 10 years and an increased risk of end-
stage renal disease (ESRD). This analysis sought to quantify the burden of RHT 
10 days since acute stroke onset, 2,000 mg was administered intravenously; from day 
11 to the end of the treatment periods (74 days), 1,000 mg was administered per os. 
The time horizon adopted in the model was 12 weeks. Based on the data on effective-
ness of citicoline in complete patient recovery after 3 months reported by A. Davalos 
et al., the cost-effectiveness ratios (CERs) were calculated and compared. Results: 
Estimated CERs were 513,099.20 RUB per one patient recovered in control group and 
435,368.00 RUB per one patient recovered in citicoline group. Furthermore, the costs 
of rehabilitation of patients were lower in the citicoline group as compared to control 
group, cost savings were estimated to be about 1,719,610.00 RUB. ConClusions: The 
study has demonstrated that the treatment of acute ischemic stroke with citicoline 
was more cost-effective and had the potential to reduce the rehabilitation expenses.
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objeCtives: Heart failure (HF) is a costly disease imposing a substantial health 
burden which affects 1-2% of Europeans. Hospital readmission for HF is a common 
occurrence with 25% of all patients readmitted within 30-days following initial 
hospitalization. Reducing readmission is an important component of managing HF 
costs and increasingly being targeted with health care policy reforms. The objec-
tive of this study is to examine how remote patient monitoring (RPM) may affect 
health care costs following the placement of a CRT-D device for patients with HF 
through the use of a simulation model. Methods: The analysis was an individual 
patient event-based simulation from a US payer perspective based on a sample 
of patients from RAPID-RF, a multi-center prospective single-arm registry which 
enrolled 889 patients who received a CRT-D and RPM system (LATITUDE® Boston 
Scientific). The modeled population consisted of patients that had at least one alert 
for weight change, atrial tachycardia or ICD shock with a subsequent interven-
tion (N= 128). The population was limited to this subset to focus on the costs of 
changes in management due to RPM. A non-RPM control group was created by 
cloning each trial patient and simulating their response in the absence of RPM to the 
conditions that triggered each alert in the trial over one year using a decision tree 
which computed rates of hospitalization and physician contacts based on literature 
data. Event and hospitalization costs were estimated per Medicare (CMS) national 
average payment. Results: RPM reduced total costs after the index procedure by 
$323/patient driven by a reduction in costs related to hospitalization admissions. 
The decrease in hospital admission cost was partially offset by RPM’s increase in 
physician visits and telephone counseling. ConClusions: RPM has the potential 
to shift HF-related care from an inpatient setting to office-based care, resulting in 
cost savings to national payers.
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objeCtives: Analysis of cost containment of SSI via use of Dabigatran Etexilate 
(150MG) versus current standard of care (Warfarin) in prevention of stroke for non 
valvular atrial fibrillation patients in Turkish health care setting. Methods: All 
calculations are performed for a group of 1000 patients in each treatment arm per 
year (Treatment arms; Dabigatran 150MG & Warfarin 5MG – results are represented 
as “cost per patient per day”). Available clinical data is analyzed for calculation of 
event costs in each treatment arm (RE-LY study). Local costs of events are included 
from local literature. Microsoft Excel (2007) is used for calculations and construc-
tion of data tables. Results: Direct cost of SSI (indirect costs are not included in 
this analysis) is calculated in each treatment arm. Difference of daily medication 
cost between Dabigatran Etexilate and Warfarin treatments is +3.12 TL/Day*Patient 
however, this difference is calculated as -3.34 TL/Day*Patient when medication 
cost is combined with total treatment cost (costs of thromboembolic&adverse 
events, INR monitoring, impairment). Dabigatran Etexilate offers a cost contain-
ment (saving) of 0.22 TL/Day*Patient in prevention of stroke for non valvular atrial 
fibrillation patients in Turkish health care setting. ConClusions: Limitation of 
this study is covering only direct cost data due to lack of local literature on indirect 
costs. Further analysis may be performed by non-interventional studies, which 
will define cost containment data via real life cost and effectiveness values. This 
study demonstrates that Dabigatran Etexilate treatment may sustain cost contain-
ment (saving) via reduction of direct cost of SSI with respect to current standard of 
care, in prevention of stroke in patients with atrial fibrillation in current Turkish 
health care system.
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objeCtives: New sutureless aortic valve prostheses reduce the surgical time. 
Objective of this study is to asses if shorter operative times may also result in 
improved patient outcomes and the impact on the hospital costs. Methods: 
Records of 547 patients that underwent aortic valve replacement with a biopros-
thesis from March 2009 and May 2013 were identified. Based on a propensity score 
analysis 2 groups (Sutureless and Sutured) with 82 matched pairs were created from 
the 112 patients received a Perceval sutureless bioprosthesis and the 435 patients 
received a sutured valve. Hospital and follow up outcomes, resources consumption 
was recorded and compared between groups. Analysis was performed according 
 VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  A521
estimate the burden of illness in PAH patients. Methods: Data came from a large 
commercial claims database. PAH patients were identified based on having > 2 medi-
cal claims for primary pulmonary hypertension (ICD-9 code:416.0), and either one 
claim for right heart catheterization or one claim of echocardiogram and diagnosed 
by a pulmonologist/cardiologist within 12 months of the medical claim. The first 
medical claim during this period served as in the index date with 12 months prior 
to this event as baseline and 12 months post as follow-up period. Demographic 
variables were extracted at a patient level from administrative files and economic 
variables, which included health care utilization and costs for outpatient, inpatient, 
emergency and pharmacy services came from the respective medical and pharmacy 
claim files and summarized at a per-patient-per-month (PPPM). Five controls were 
randomly picked and matched to each PAH patient on demographic characteristics. 
Incremental burden of PAH was estimated using non-parametric statistical tests 
between controls and PAH group. All costs were adjusted to 2012 base year using 
consumer price index. Results: A total of 2,245 PAH patients were identified and 
matched to 11,225 controls. PAH group had significantly higher (p< 0.001) PPPM 
health care utilization compared to the matched control across all drivers: outpa-
tient (2.6 vs. 1.5), inpatient (0.08 vs. 0.02), emergency room (0.1 vs. 0.04), and phar-
macy services (4.2 vs. 2.6). The increase in utilization translated in higher (p< 0.001) 
total PPPM incremental costs of $3,193 in the PAH group with inpatient ($1,665 
vs. $345) and pharmacy costs ($790 vs. $178) being as much as five times greater 
compared to controls. ConClusions: Health care resource use and costs for PAH 
patients is high from a managed care perspective.
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objeCtives: To describe the incidence and profile of patients hospitalised for acute 
heart failure (AHF); to assess the trajectories of patients before and after hospitaliza-
tion; and to estimate the cost of AHF inpatients stays. Methods: Patients with AHF 
were identified over a 5-year period (2006 - 2010) from the French PMSI (Programme 
de Médicalisation des Systèmes d’Information), a national disease-related group 
inpatient database. The PMSI database contains data related to all private and public 
hospital stays in France (about 20 millions/year). Heart failure was identified with 
the ICD-10, code I50. Results: The numbers of patients hospitalised at least once 
per year for AHF increased from 144,043 in 2006 to 158,623 in 2010. These num-
bers lead to incidence rates of 2.28‰ in 2006 and 2.45‰ in 2010. The proportion of 
patients aged ≥ 75 increased from 71.0% in 2006 to 74.3% in 2010. Half of patients 
were male. The mean number of comorbidities was 9.6 in 2010. The mean length of 
stay was 9.5 days and 12.6 days per year (2010), as mean re-hospitalization for AHF 
within the same year was 22%. The mean annual number of AHF hospitalisations 
per patient was 1.3. The mean cost for an AHF hospitalisation in the acute setting 
was 4,713€ in 2010. The mean annual cost for all hospitalisations occurring for a 
patient hospitalised at least once in a year (2010) for AHF was 6,253€ . Mean costs 
per hospital stay was higher if the patient died during hospitalisation (5,722€ vs. 
4,627€ , p< 0.001). Extrapolation to the whole country leads to a yearly cost of nearly 
a billion of euros (991 millions). ConClusions: Incidence of AHF hospitalisation 
increased in the recent years. This analysis highlighted the high economic hospital 
burden of AHF in France.
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objeCtives: Stroke has catastrophic consequences resulting in death or disability 
in 80% of patients and representing a substantial burden on the health care system, 
as well as on patients, family, and society. Stroke is considered as the 2ndcause of 
burden of disease in Europe and ischemic stroke (IS) represents a high percent-
age of total strokes. The objective of the present study was to analyze the first 
year post-stroke burden of IS in Spain. Methods: We performed an observational, 
multicenter, naturalistic and prospective study that included 16 hospitals (stroke 
units of National Health System hospitals) of 16 Spain regions. We took into con-
sideration consumption of health care resources, social burden, productivity lost 
and health-related quality of live of patient and caregiver during the first year 
post-stroke. Results: A total of 321 stroke patients were recruited. Mean age 72 
years, 54.8% male. Basal NIH stroke scale was 9.11 and 28.9% presented moderate-
high disability. 291 (90.7%) patients presented IS. Overall 1-year cost per IS was 
27,596.53€ . Direct health care costs were 8,623.35€ (31.25%), direct intrahospital 
health care costs supposed 69% (5,926.21€ ) of these costs. Direct non-health care 
costs were 18,377.75€ (66.59%), of which 16,515.09€ (59.84%) were informal care 
costs. Productivity lost was 595.43€ (2.16%). ConClusions: IS were the majority 
of total strokes in the study and represent a high burden on health care system and 
society, mainly due to hospitalization and informal care costs. Intrahospital costs 
were double than the published DRGs in Spain. Other diseases like Alzheimer or 
dementia represent a lower burden than stroke.
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objeCtives: To review published estimates of post-acute-care costs over one year 
in patients with acute coronary syndrome (ACS). Methods: Using the Medline and 
in EU5, a subject about which nothing has been published to date. Methods: A 
burden of illness model was constructed to examine the impact of RHT in EU5, 
specifically the incremental incidence, mortality and direct medical costs of CVD, 
which includes: coronary heart disease (CHD), congestive heart failure (CHF) and 
stroke. Framingham risk equations which included a coefficient for treatment resist-
ance and SCORE risk charts were used to estimate the risk of CVD for patients 
with and without RHT. Transition probability data were taken from the literature 
to estimate the risk of death from CVD events, subsequent CVD events and ESRD. 
Direct costs for these events and their long-term consequences were taken from 
the literature and from country-specific drug and acute inpatient costs. Results: 
The total direct medical cost of RHT in EU5 is estimated to be € 3.9 billion in 2013. 
This does not include the cost for drugs to treat RHT, or other costs such as lost 
productivity not directly borne by the health care system. RHT will contribute to 
188,000 cases of CHD, 57,400 strokes, 31,500 CHF and 1,400 ESRD and 30,000 deaths 
in 2013. ConClusions: The burden of RHT due to the increased incidence of CVD 
and ESRD is high. Reducing the incidence of CVD and ESRD through better blood 
pressure control should be a priority for health care decision makers.
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objeCtives: To analyze and estimate resource utilization and associated costs, 
one year following an acute episode of heart failure (HF) in Spain. Methods: 
Patient-flow data after index hospitalization for acute HF (AHF) were obtained 
from EAHFE database, an emergency (ER)-based registry containing records of all 
AHF patients treated in 29 Spanish hospitals (over 5,800 cases). Estimated medical 
resource utilization data during patients’ ER and other wards stay, hospitalization, 
and first-year follow-up was collected from medical specialists through question-
naire. AHF episodes and hospitalizations incident rates were estimated through 
literature review and disease statistics in official sources. Cost data was retrieved 
from Spanish Pharmacists official sources and a national health care costs database 
(Euros, 2013). To assess uncertainty, sensitivity analysis was carried out. Results: 
A total of 111,803 annual hospital admissions are estimated in Spain (2013). 92% 
of patients suffering an AHF episode are discharged alive and of these 90% survive 
the first month; 23% of these patients are discharged directly from ER, while the 
majority of those who are hospitalized, are admitted to Internal Medicine (53%) or 
Cardiology (17%) wards. On an average, patients are re-admitted 0.41 times within 1 
year. Total direct costs in the first year following an AHF episode averages € 6,822, of 
which 88% are incurred in hospital, with drugs and diagnostic tests accounting for 
less than 5% of all hospital costs. Follow-up costs, in average, split equally between 
drugs and outpatient visits/tests, but vary widely depending on local HF protocols. 
Extrapolation of results to the Spanish population suggests that the total burden of 
HF is more than € 542 million per year. ConClusions: Treating HF patients within 
Spain is resource intensive. Costs are primarily incurred in hospital and are mostly 
driven by the length of stay.
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objeCtives: Chronic thromboembolic hypertension (CTEPH) is associated with 
considerable morbidity and mortality. The objective of this study was to describe the 
burden of illness in patients with CTEPH. Methods: Data for this study came from 
a large commercial claims database. CTEPH patients were identified based on having 
> 2 medical claims for either primary pulmonary hypertension (ICD-9 code:416.0) or 
chronic pulmonary heart disease (ICD-9 code:416.8), history of pulmonary embolism 
in the past one year (ICD-9 code:415.1, V12.51, 38.7; CPT-4 codes:36010, 37620, 75825, 
75940; HCPCS codes:C1880) and either one claim for right heart catheterization 
or one claim of echocardiogram and diagnosed by a pulmonologist/cardiologist 
within 12 months of the medical claim. Demographic variables were extracted at 
a patient level from administrative files and economic variables, which included 
health care utilization and costs for outpatient, inpatient, emergency and pharmacy 
services came from the respective medical and pharmacy claim files and sum-
marized at a per-patient-per-month (PPPM). Five controls were randomly picked 
and matched to each CTEPH patient on demographic characteristics. Incremental 
burden of CTEPH was estimated using non-parametric statistical tests between 
controls and CTEPH group. All costs were adjusted to 2012 base year using consumer 
price index. Results: A total of 191 CTEPH patients were identified and matched 
to 955 controls. CTEPH group had significantly higher (p< 0.001) PPPM health care 
utilization compared to the matched control across all drivers: outpatient (3.1 vs. 
1.5), inpatient (0.13 vs. 0.02), emergency room (0.16 vs. 0.04), and pharmacy services 
(4.5 vs. 2.6). The increase in utilization translated in higher (p< 0.001) total PPPM 
incremental costs of $5,007 in the CTEPH group with inpatient ($3,909 vs. $332) and 
pharmacy costs ($607 vs. $180) being as much as twelve and three times greater 
compared to controls. ConClusions: Health care resource use and costs for CTEPH 
patients is high from a managed care perspective.
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objeCtives: Pulmonary arterial hypertension (PAH) is a progressive disease result-
ing in high health care resource use and costs. The objective of this study was to 
